Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide and Radiation Therapy in Treating Patients With Gliomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed\* supratentorial glioma of 1 of the following histologies:~  * Astrocytoma (diffuse fibrillary, protoplasmic, or gemistocytic)~ * Oligodendroglioma~ * Oligoastrocytoma Note: \*Histologic atypia allowed provided no other histologic features (i.e., frequent mitoses, endothelial proliferation, and/or acute necrosis) that would result in a designation of anaplastic astrocytoma, anaplastic mixed oligodendroglioma or oligoastrocytoma, or glioblastoma multiforme are present~* Unifocal or multifocal disease~* World Health Organization (WHO) grade II disease~* Neurofibromatosis allowed~* Surgical biopsy or resection for tumor tissue sampling required within the past 12 weeks~  * Tissue block or core biopsy available for O6-methylguanine-DNA methyltransferase analysis and tissue banking~ * Patients who have only had a stereotactic biopsy are not eligible~* Must have ≥ 3 of the following risk factors:~  * Age 40 and over~ * Largest preoperative tumor diameter ≥ 6 cm~ * Tumor crosses the midline~ * Astrocytoma-dominant tumor subtype~ * Preoperative Neurological Function Status \> 1~* No other low-grade glioma histologies, including any of the following:~  * Pilocytic astrocytoma~ * Subependymal giant cell astrocytoma of tuberous sclerosis~ * Subependymoma~ * Pleomorphic xanthoastrocytoma~ * Presence of a neuronal element, such as ganglioglioma~ * Dysneuroembryoplastic epithelial tumor~* No high-grade glioma, including any of the following:~  * Anaplastic astrocytoma~ * Glioblastoma multiforme~ * Anaplastic oligodendroglioma~ * Anaplastic oligoastrocytoma~* No tumors in any non-supratentorial location, including any of the following:~  * Optic chiasm~ * Optic nerve(s)~ * Pons~ * Medulla~ * Cerebellum~ * Spinal cord~* No evidence of disease progression to spinal meninges or noncontiguous cranial meninges (i.e., leptomeningeal gliomatosis) by MRI of the spine or cerebrospinal fluid (CSF) cytology~  * MRI of the spine or CSF cytology are not required for patients without symptoms of spinal/cranial meningeal disease progression~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Total bilirubin ≤ 1.5 mg/dL~* Serum glutamate oxaloacetate transaminase (SGOT) or Serum glutamate pyruvate transaminase (SGPT) ≤ 2 times normal~* Alkaline phosphatase ≤ 2 times normal~Renal~* Serum creatinine ≤ 1.5 mg/dL~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known HIV positivity~* No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanoma skin cancer~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunotherapy or biologic therapy~Chemotherapy~* No prior chemotherapy~* No other concurrent chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy to the head and neck unless head and neck radiotherapy clearly excluded the brain (e.g., localized radiotherapy to the vocal cords)~* No prior radiotherapy to the brain~* No concurrent intensity modulated radiotherapy~* No concurrent stereotactic boost radiotherapy~Surgery~* See Disease Characteristics~Other~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temozolomide + Radiation Therapy (RT) (Type: EXPERIMENTAL): Daily temozolomide plus concurrent radiotherapy followed by temozolomide

Based on this trial design, predict the completion outcome and termination type (if applicable).